Quote this publication Share Print

XARELTO

-
Opinions on drugs - Posted on Mar 14 2012

Reason for request

Inclusion on the list of medicines refundable by National Health Insurance (B/14, B/28 and B/42 for the 15 mg/tablet dosage and B/14 and B/28 for the 20 mg/tablet dosage) and approved for hospital use (B/10 and B/100 for both dosages) in the extension of indication: “Treatment of deep venous thrombosis (DVP) and prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVP in adults”.

-


Actual benefit

Important

The actual benefit of XARELTO (rivaroxaban) is substantial in the treatment of deep venous thrombosis (DVT) and in the prevention of recurrence of DVT and pulmonary embolism (PE) following acute DVT in adults.


Improvement in actual benefit

V (absence)

XARELTO does not provide an improvement in actual benefit (IAB level V) in the treatment of acute deep venous thrombosis and in the prevention of the recurrence of DVT and pulmonary embolism (PE).


Contact Us

Évaluation des médicaments